Stifel raised the firm’s price target on Trevi Therapeutics (TRVI) to $18 from $15 and keeps a Buy rating on the shares as part of a 2026 outlook note for the analyst’s Biopharma coverage.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics Appoints New Chief Financial Officer
- Trevi Therapeutics appoints David Hastings as CFO
- Positive Developments and Strategic Advancements Boost Trevi Therapeutics’ Buy Rating
- Trevi Therapeutics price target raised to $16 from $13 at Leerink
- Trevi Therapeutics’ Earnings Call Highlights Promising Outlook